IRIS
GERETTI, ANNA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.883
AS - Asia 4.599
EU - Europa 1.379
Continente sconosciuto - Info sul continente non disponibili 857
SA - Sud America 724
AF - Africa 77
OC - Oceania 6
Totale 13.525
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.700
SG - Singapore 1.892
HK - Hong Kong 862
CN - Cina 658
BR - Brasile 592
RU - Federazione Russa 420
IT - Italia 365
VN - Vietnam 360
BD - Bangladesh 319
JP - Giappone 278
FI - Finlandia 144
DE - Germania 77
FR - Francia 73
CA - Canada 66
IN - India 66
MX - Messico 61
GB - Regno Unito 58
AR - Argentina 55
SE - Svezia 55
UA - Ucraina 35
ID - Indonesia 30
NL - Olanda 28
AT - Austria 25
ZA - Sudafrica 25
IE - Irlanda 24
CO - Colombia 22
PL - Polonia 21
EC - Ecuador 17
PK - Pakistan 17
IR - Iran 16
JM - Giamaica 16
CR - Costa Rica 15
ES - Italia 14
IQ - Iraq 14
PY - Paraguay 12
TR - Turchia 12
TN - Tunisia 10
AZ - Azerbaigian 9
CL - Cile 9
CH - Svizzera 8
EG - Egitto 8
KR - Corea 8
MA - Marocco 7
PE - Perù 7
AE - Emirati Arabi Uniti 6
JO - Giordania 6
SA - Arabia Saudita 6
AU - Australia 5
KE - Kenya 5
MY - Malesia 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
UZ - Uzbekistan 5
VE - Venezuela 5
ET - Etiopia 4
HN - Honduras 4
LT - Lituania 4
MW - Malawi 4
NI - Nicaragua 4
OM - Oman 4
PH - Filippine 4
TH - Thailandia 4
AL - Albania 3
CM - Camerun 3
DO - Repubblica Dominicana 3
GR - Grecia 3
HR - Croazia 3
NP - Nepal 3
RO - Romania 3
SK - Slovacchia (Repubblica Slovacca) 3
BB - Barbados 2
BE - Belgio 2
BG - Bulgaria 2
DZ - Algeria 2
GH - Ghana 2
HU - Ungheria 2
IL - Israele 2
LB - Libano 2
LC - Santa Lucia 2
MT - Malta 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
ZW - Zimbabwe 2
AM - Armenia 1
BN - Brunei Darussalam 1
BZ - Belize 1
CG - Congo 1
CI - Costa d'Avorio 1
CU - Cuba 1
DK - Danimarca 1
GD - Grenada 1
GT - Guatemala 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
KY - Cayman, isole 1
KZ - Kazakistan 1
Totale 12.664
Salva come PNG Salva come JPEG
Città #
San Jose 976
Hong Kong 844
Singapore 661
Woodbridge 566
Council Bluffs 509
Houston 509
Wilmington 476
Ashburn 298
Tokyo 273
Los Angeles 182
Beijing 167
The Dalles 134
Ho Chi Minh City 121
Buffalo 114
Helsinki 114
Redondo Beach 99
Dallas 98
New York 95
Fairfield 76
Hanoi 70
Moscow 67
Chicago 65
Rome 57
Ann Arbor 56
Santa Clara 56
Mexico City 40
Seattle 39
North Bergen 34
Phoenix 34
São Paulo 33
Milan 32
Cambridge 31
Lauterbourg 30
Jacksonville 26
Salt Lake City 23
Dublin 22
Lappeenranta 22
Boardman 18
Haiphong 17
Orem 17
Atlanta 16
Frankfurt am Main 15
Naples 15
Tehran 15
Johannesburg 14
Medford 14
Nuremberg 14
Philadelphia 14
Rio de Janeiro 14
Chandler 13
Elk Grove Village 13
Kraków 13
Stockholm 13
Brooklyn 12
Da Nang 12
Dearborn 12
London 12
Shaoxing 12
Amsterdam 11
Belo Horizonte 11
Brasília 11
Denver 11
Bologna 10
Genoa 10
Changsha 9
Florence 9
Hefei 9
Queens 9
San Francisco 9
San José 9
Sterling 9
Vienna 9
Baku 8
Guarulhos 8
Miami 8
Montreal 8
Quito 8
Ribeirão Preto 8
Salvador 8
Tampa 8
Zhengzhou 8
Bari 7
Biên Hòa 7
Chennai 7
Dulles 7
Fort Wayne 7
Fortaleza 7
Kingston 7
Lawrence 7
Menlo Park 7
Munich 7
Shanghai 7
Staten Island 7
The Bronx 7
Zurich 7
Ajax 6
Baghdad 6
Bogotá 6
Bắc Ninh 6
Charlotte 6
Totale 7.680
Salva come PNG Salva come JPEG
Nome #
European guidelines on the clinical management of HIV-1 tropism testing 457
When and how to use maraviroc in HIV-infected patients 457
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: A multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing 411
Emerging patterns and implications of HIV-1 integrase inhibitor resistance 405
Optimal use of maraviroc in clinical practice 389
The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis 275
Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants 260
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy 206
Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution 189
2024 European guidelines for the management of genital herpes 170
Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: A cross-sectional comparison with the general population 112
Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection 107
A contaminant-free assessment of Endogenous Retroviral RNA in human plasma 89
Plasma HIV-1 RNA detection below 50 copies/mL and risk of virologic rebound in patients receiving highly active antiretroviral therapy 88
The evolving landscape of COVID-19: Factors associated with in-hospital COVID-19 related mortality during the 2023-2024 phase of JN.1 subvariant dominance 83
A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action 83
A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance 82
British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015 80
Diagnostic performance evaluation of hepatitis B e antigen rapid diagnostic tests in Malawi 79
Research news in clinical context 75
Epidemiology of hepatitis B, C and D in Malawi: Systematic review 11 Medical and Health Sciences 1117 Public Health and Health Services 11 Medical and Health Sciences 1108 Medical Microbiology 11 Medical and Health Sciences 1103 Clinical Sciences 72
Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection 71
PATHWAYS UNDERLYING HDV PERSISTENCE ACT INDEPENDENTLY FROM THE EXTENT OF HBV RESEVOIR AND ARE SUSTAINED BY AN ABUNDANT PRODUCTION OF HBSAG DERIVED FROM INTEGRATED HBV-DNA P 214 70
The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir 69
Liver Fibrosis by Transient Elastography and Virologic Outcomes after Introduction of Tenofovir in Lamivudine-Experienced Adults with HIV and Hepatitis B Virus Coinfection in Ghana 68
Alcohol, smoking, recreational drug use and association with virological outcomes among people living with HIV: cross-sectional and longitudinal analyses 68
Age, time living with diagnosed HIV infection, and self-rated health 65
Chronic HDV infection is sustained by an intense HBsAg production fromintegrated HBVDNA in the setting of a limited or even absent HBV reservoir. 64
Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa 64
Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom 64
Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance- a phase IV randomised, open-label study (PIBIK study). 62
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process 62
A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi, suggests a historic mechanism of transmission 61
Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study 61
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-na{\"i}ve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): Study protocol for a randomised trial 60
Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia 59
HBsAg production from integrated HBV-DNA sustains HDV persistence in the setting of a limited or even absent HBV reservoir 59
Safety and pharmacokinetic characterization of nacubactam, a novel ?-lactamase inhibitor, alone and in combination with meropenem, in healthy volunteers 58
HDV persistence is sustained by HBsAg mainly derived from integrated HBV-DNA and is independent from the extent of HBV reservoir 58
Factors associated with persistence of plasma HIV-1 RNA during long-term continuously suppressive firstline antiretroviral therapy 57
Pathways sustaining HDV activity act independently from the size of HBV resevoir and are fueled by an abundant expression of HBsAg from integrated HBV-DNA 57
Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis 56
Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK 55
Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression 55
Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey 55
Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: Results from the cross-sectional ASTRA study 54
HIV-1 subtypes: Epidemiology and significance for HIV management 54
Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy 54
Causes, associated exposures, and outcomes of cirrhosis and hepatocellular carcinoma in Malawi: an observational cohort and case–control study 53
A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients 52
Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data 52
Attitudes of people in the UK with HIV who are antiretroviral (ART) na{\"i}ve to starting art at high CD4 counts for potential health benefit or to prevent HIV transmission 52
During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ 52
Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation 51
The gamma-glutamyl transpeptidase to platelet ratio (GPR) shows poor correlation with transient elastography measurements of liver fibrosis in HIV-positive patients with chronic hepatitis B in West Africa. Response to: {'}The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa{'} by Lemoine et al 51
An apparent paradox: Resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy 51
Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIVPositive adults receiving first-line antiretroviral therapy in Malawi 51
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study 51
2014 European guideline on HIV testing 50
Primary herpes simplex virus type-2 infection as a cause of liver failure after liver transplantation 50
HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults 50
Accuracy of self-report of HIV viral load among people with HIV on antiretroviral treatment 49
Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz 49
HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination 49
Occult hepatitis B virus coinfection in HIV-positive African migrants to the UK: A point prevalence study 48
Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades 48
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment 48
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook 48
Kinetics and Specificities of the T Helper?Cell Response to GP120 in the Asymptomatic Stage of HIV-1 Infection 47
Hepatitis B virus infection in general practice across England: An analysis of the Royal College of General Practitioners Research and Surveillance Centre real-world database 47
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight) 47
Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection 47
Measuring Proviral HIV-1 DNA: Hurdles and Improvements to an Assay Monitoring Integration Events Utilising Human Alu Repeat Sequences 46
Antibody screening tests variably overestimate the prevalence of hepatitis C virus infection among HIV-infected adults in Ghana 46
2017 European guidelines for the management of genital herpes 45
Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation 45
Cytotoxic T lymphocytes in AIDS pathogenesis: Lessons to be learned from the macaque model of simian immunodeficiency virus infection 45
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions 45
Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses 45
Antiretroviral resistance in clinical practice 44
A virological perspective on resistance in highly treatment-experienced patients 44
Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia 44
Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring 44
Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana 44
Efficacy of once daily darunavir/ritonavir in PI-Na{\"i}ve, NNRTI-experienced patients in the ODIN trial 44
Liver steatosis and fibrosis in people with human immunodeficiency virus in West Africa and the relationship with hepatitis B virus coinfection 43
Real-world prevalence of non-integrase INSTI resistance-associated mutations and virological outcomes in people who have recently acquired HIV-1 in the UK 43
The impact of HIV drug resistance testing on changes to treatment 43
Prevalence and characteristics of hepatitis B virus (HBV) coinfection among HIV-Positive women in South Africa and Botswana 43
Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy 43
Development of a real-time multiplex RSV detection assay for difficult respiratory samples, using ultrasone waves and MNAzyme technology 43
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 42
Prospective pilot study on the relationship between seminal HIV-1 shedding and genital schistosomiasis in men receiving antiretroviral therapy along Lake Malawi 42
Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV positive adults in Ghana 42
Emergent Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens 42
British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008 42
HIV DNA Sequencing to Detect Archived Antiretroviral Drug Resistance 41
Point-of-Care Screening for a Current Hepatitis C Virus Infection: Influence on Uptake of a Concomitant Offer of HIV Screening 41
High prevalence of latent tuberculosis and bloodborne virus infection in a homeless population 41
Antiretroviral resistance 41
Totale 8.215
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.870
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.870
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202277 0 0 17 2 1 8 3 7 15 4 4 16
2022/202357 8 0 0 6 4 20 6 2 5 0 6 0
2023/202419 3 0 0 0 0 2 0 0 0 10 0 4
2024/20253.043 6 36 28 10 3 59 67 716 886 271 575 386
2025/20267.419 503 473 864 441 413 177 692 1.029 1.145 635 723 324
2026/20271.007 470 516 21 0 0 0 0 0 0 0 0 0
Totale 13.525